Literature DB >> 26711243

Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.

Li-Che Lu1,2, Chung-Wei Yang1,3, Wen-Yeh Hsieh4, Wan-Hsuan Chuang1, Yi-Chang Lin1, Chih-Sheng Lin5.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs) play important roles in the pathophysiology of renal diseases. Imbalanced MMPs/TIMPs are implicated in the vascular alterations of uremic patients on hemodialysis (HD). We have investigated the plasma levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 in uremic patients and the effects of a course of HD on the changes in these factors.
METHODS: There were 382 uremic patients on regular HD treatment and 50 healthy controls enrolled in this study. The plasma MMP-2 and MMP-9 levels were detected by gelatin zymography, and TIMP-1 and TIMP-2 concentrations were determined by ELISA assay.
RESULTS: Significantly higher plasma MMP-2 and MMP-9 and decreased TIMP-1 in the uremic patients were detected compared with those in the controls. Therefore, there were markedly higher MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in the uremic patients. In the course of a single HD session, the plasma MMP-2 level was significantly decreased from pre-HD to post-HD. TIMP-1 concentration was significantly increased from pre-HD to post-HD. Although the HD session did not have a significant effect on the levels of plasma MMP-9 and TIMP-2, both plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios were significantly decreased from pre-HD to post-HD levels.
CONCLUSION: HD session could decrease MMP-2 and increase TIMP-1 level in the circulation of uremic patients. The physiological significance of reduced MMPs/TIMPs ratio due to a single HD session is required to further validate.

Entities:  

Keywords:  Hemodialysis; Matrix metalloproteinase; Tissue inhibitor of matrix metalloproteinase; Uremic patient

Mesh:

Substances:

Year:  2015        PMID: 26711243     DOI: 10.1007/s10157-015-1221-0

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  37 in total

Review 1.  Treatment targets in renal fibrosis.

Authors:  Peter Boor; Katarína Sebeková; Tammo Ostendorf; Jürgen Floege
Journal:  Nephrol Dial Transplant       Date:  2007-09-21       Impact factor: 5.992

Review 2.  Targeting matrix metalloproteinases in inflammatory conditions.

Authors:  A L Clutterbuck; K E Asplin; P Harris; D Allaway; A Mobasheri
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

3.  Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis.

Authors:  Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Journal:  Clin Biochem       Date:  2011-04-16       Impact factor: 3.281

Review 4.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

5.  Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

Authors:  Raquel F Gerlach; Caroline Demacq; Klaus Jung; Jose E Tanus-Santos
Journal:  Clin Biochem       Date:  2006-10-19       Impact factor: 3.281

6.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.

Authors:  S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

7.  Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm.

Authors:  T Grzela; R Brawura-Biskupski-Samaha; M M Jelenska; J Szmidt
Journal:  Eur J Vasc Endovasc Surg       Date:  2007-10-26       Impact factor: 7.069

8.  Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease.

Authors:  Ada W Y Chung; H H Clarice Yang; Jong Moo Kim; Mhairi K Sigrist; Elliott Chum; William A Gourlay; Adeera Levin
Journal:  Circulation       Date:  2009-08-17       Impact factor: 29.690

9.  Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells.

Authors:  Kalliopi Zafeiropoulou; Theodora Bita; Apostolos Polykratis; Stella Karabina; John Vlachojannis; Panagiotis Katsoris
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

10.  Circulating matrix metalloproteinase-2 and -9 enzyme activities in the children with ventricular septal defect.

Authors:  Kun-Shan Cheng; Yan-Chiou Liao; Mu-Yuan Chen; Tang-Ching Kuan; Yi-Han Hong; Li Ko; Wen-Yeh Hsieh; Chien-Liang Wu; Ming-Ren Chen; Chih-Sheng Lin
Journal:  Int J Biol Sci       Date:  2013-06-12       Impact factor: 6.580

View more
  6 in total

1.  Upregulated expression of MMP-9 in gingival epithelial cells induced by prolonged stimulation with arecoline.

Authors:  Osamu Uehara; Kousuke Takimoto; Tetsuro Morikawa; Fumiya Harada; Rie Takai; Bhoj Raj Adhikari; Ryoko Itatsu; Tomohisa Nakamura; Koki Yoshida; Hirofumi Matsuoka; Hiroki Nagayasu; Ichiro Saito; Malsantha Muthumala; Itsuo Chiba; Yoshihiro Abiko
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

2.  Curcumin inhibits the expression of proinflammatory mediators and MMP-9 in gingival epithelial cells stimulated for a prolonged period with lipopolysaccharides derived from Porphyromonas gingivalis.

Authors:  Seiko Toraya; Osamu Uehara; Daichi Hiraki; Fumiya Harada; Puja Neopane; Tetsuro Morikawa; Rie Takai; Koki Yoshida; Hirofumi Matsuoka; Nobuyoshi Kitaichi; Itsuo Chiba; Yoshihiro Abiko
Journal:  Odontology       Date:  2019-05-13       Impact factor: 2.634

3.  Inflammatory response and matrix metalloproteinases in chronic kidney failure: Modulation by adropin and spexin.

Authors:  Burak Yazgan; Filiz Avcı; Gülsün Memi; Ebru Tastekin
Journal:  Exp Biol Med (Maywood)       Date:  2021-05-22

4.  Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice.

Authors:  Chung-I Lin; Chin-Hung Tsai; Yu-Ling Sun; Wen-Yeh Hsieh; Yi-Chang Lin; Cheng-Yi Chen; Chih-Sheng Lin
Journal:  Int J Biol Sci       Date:  2018-02-12       Impact factor: 6.580

5.  Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy.

Authors:  Elena Rodríguez-Sánchez; José Alberto Navarro-García; Jennifer Aceves-Ripoll; Judith Abarca-Zabalía; Andrea Susmozas-Sánchez; Teresa Bada-Bosch; Eduardo Hernández; Evangelina Mérida-Herrero; Amado Andrés; Manuel Praga; Mario Fernández-Ruiz; José María Aguado; Julián Segura; Luis Miguel Ruilope; Gema Ruiz-Hurtado
Journal:  Biomolecules       Date:  2020-03-26

6.  Correlations between serum inflammatory markers and comorbidities in patients with end-stage renal disease.

Authors:  Asmahan K Eloueyk; Rashad Y Alameddine; Bilal A Osta; Dania M Awad
Journal:  J Taibah Univ Med Sci       Date:  2019-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.